Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center.

Transl Lung Cancer Res · 2024 · PMC10891410 · PMID 38405002

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, our study did not find a significant difference in postoperative RFS between ALK-TKI and chemotherapy in pathologically nodal positive patients, but adjuvant ALK-TKI showed a trend toward a lower risk of recurrence.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.